Celularity and Regeneron to collaborate in Florham Park on multiyear cell therapy research

Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy

Celularity Inc., a Florham Park-based biotechnology company, on Tuesday said it has entered into a multiyear research collaboration services agreement with Basking Ridge-based Regeneron Pharmaceuticals.

The agreement’s initial focus is the research on a targeted allogeneic gamma delta chimeric antigen receptor, or CAR, T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors.

The research will take place at Celularity’s Florham Park facility.

Financial terms were not disclosed.

“The agreement with Regeneron announced today is an important milestone for Celularity that recognizes our expertise in the research of cellular therapies, including the engineering of CAR-T cells. We believe that this relationship paves the way for future industry collaborations leveraging our world-class cell therapy facilities and capabilities,” Dr. Robert Hariri, Celularity’s founder, chairman and CEO, said. “We have long admired the exceptional scientific legacy at Regeneron and welcome the opportunity to collaborate with a world leader in innovative medicines.”

Celularity, headquartered in Florham Park, is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using mesenchymal-like adherent stromal cells, or MLASCs, T-cells engineered with CAR, and genetically modified and unmodified natural killer, or NK, cells. These therapeutic programs target indications in autoimmune, infectious and degenerative diseases,